ClinicalTrials.gg
Status unknownNCT02321267Updated Mar 7, 2018

Cohort Study of the Clinical Course of Macular Diseases in Kagawa

A Phase 4 interventional study of ranibizumab, aflibercept, pegaptanib, verteporphin in Macular Disease, sponsored by Kagawa University. Status unknown at 1 site in Japan. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by Kagawa University · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Planned enrollment
5th of 124
1,000 · median 64
Started
2014
with 9 others
Phase 4
33 of 125
none open now
Registered
98th of 125
by date

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 5th largest by planned enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2014, is one of 33 in phase 4, and was the 98th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS).

Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

03

Conditions studied

  • Macular Disease

Keywords

  • AMD
  • PCV
  • RAP
  • RVO
  • DME
  • ERM
  • MH
  • mCNV
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who visit Department of Ophthalmology, Kagawa University Hospital with macular diseases, such as AMD, PCV, RAP, RVO, DME, ERM, MH, VMTS.
  • Patients who are agreed with the participation of this study.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    Macular disease with adequate treatments

    Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.

    Drug: ranibizumab, aflibercept, pegaptanib, verteporphin

Interventions

06

What researchers measure

Primary outcomes

  1. Change of best-collected visual acuity from baseline at 5 years

    Time frame: Five years after the registration

07

Study locations

1 of 1 sites recruiting
  • Kagawa University Faculty of Medicine
    Miki, Kagawa 761-0793, Japan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Dec 2024 and a completion of Dec 2024. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2014
First posted
Dec 22, 2014
Start
Dec 2014
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Mar 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02321267
Lead sponsor
Kagawa University
Responsible party
Akitaka Tsujikawa (Professor and Chairman, Kagawa University) — Principal investigator
First posted
Dec 22, 2014
Start date
Dec 2014
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 7, 2018

Study contacts

Chika Akuta
Contact
kaomie@med.kagawa-u.ac.jp
+81-87-891-2211
Akiataka Tsujikawa, MD
principal investigator · Kagawa Univerisity Faculty of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ranibizumab · Aflibercept · Pegaptanib · Verteporfin

Start the discussion